Tarsons Products Ltd
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
- Market Cap ₹ 1,166 Cr.
- Current Price ₹ 219
- High / Low ₹ 458 / 188
- Stock P/E 54.9
- Book Value ₹ 118
- Dividend Yield 0.00 %
- ROCE 6.91 %
- ROE 4.75 %
- Face Value ₹ 2.00
Pros
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 229 | 301 | 296 | 392 | 414 | |
| 125 | 148 | 196 | 282 | 294 | |
| Operating Profit | 103 | 153 | 100 | 111 | 121 |
| OPM % | 45% | 51% | 34% | 28% | 29% |
| 5 | 8 | 11 | 16 | 20 | |
| Interest | 3 | 4 | 10 | 20 | 22 |
| Depreciation | 14 | 22 | 40 | 62 | 87 |
| Profit before tax | 92 | 135 | 61 | 45 | 32 |
| Tax % | 25% | 25% | 30% | 34% | |
| 69 | 101 | 43 | 30 | 20 | |
| EPS in Rs | 3,583.25 | 18.92 | 8.01 | 5.60 | 3.82 |
| Dividend Payout % | 0% | 0% | 25% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -34% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -32% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.19 | 11 | 11 | 11 | 11 |
| Reserves | 244 | 479 | 602 | 620 | 616 |
| 34 | 22 | 269 | 339 | 396 | |
| 18 | 33 | 90 | 111 | 141 | |
| Total Liabilities | 296 | 544 | 972 | 1,080 | 1,164 |
| 120 | 189 | 336 | 536 | 583 | |
| CWIP | 22 | 32 | 267 | 233 | 251 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 153 | 323 | 369 | 311 | 330 | |
| Total Assets | 296 | 544 | 972 | 1,080 | 1,164 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 68 | 83 | 103 | 114 | |
| -64 | -138 | -285 | -145 | |
| -27 | 130 | 136 | 39 | |
| Net Cash Flow | -23 | 75 | -47 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 75 | 79 | 96 | 74 |
| Inventory Days | 277 | 478 | 572 | 355 |
| Days Payable | 35 | 75 | 65 | 44 |
| Cash Conversion Cycle | 317 | 482 | 602 | 385 |
| Working Capital Days | 108 | 150 | -1 | 38 |
| ROCE % | 35% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Audio of Feb 6, 2026 investor conference call for Q3/9M FY26 results uploaded; transcript to follow.
-
Announcement Of Equity Infusion In Our Wholly Owned Subsidiary Based In Singapore
2d - Approved Q3/9M results; EUR 3M equity infusion to Singapore subsidiary; independent director change Feb 06, 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Of Investor Presentation for the Quarter and Nine months ended December 31, 2025
-
Announcement under Regulation 30 (LODR)-Resignation of Director
2d - Q3/9M results approved; EUR3M to Singapore subsidiary; Kriplani appointed; Vanvari resigned; committees reconstituted.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Unaudited Q3/9M results; EUR3M equity to Singapore subsidiary; new independent director; Girish Vanvari resigned Feb 6, 2026.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptAI SummaryPPT
-
Dec 2023TranscriptPPTREC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)